793 related articles for article (PubMed ID: 15149150)
1. Successful treatment of refractory anemia with a combination regimen containing recombinant human erythropoietin, low-dose methylprednisolone and nandrolone.
Tsiara SN; Chaidos A; Gouva M; Christou L; Panteli K; Kapsali E; Bourantas KL
J Exp Clin Cancer Res; 2004 Mar; 23(1):47-52. PubMed ID: 15149150
[TBL] [Abstract][Full Text] [Related]
2. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.
Remacha AF; Arrizabalaga B; Villegas A; Manteiga R; Calvo T; Julià A; Fernández Fuertes I; González FA; Font L; Juncà J; del Arco A; Malcorra JJ; Equiza EP; de Mendiguren BP; Romero M
Haematologica; 1999 Dec; 84(12):1058-64. PubMed ID: 10586205
[TBL] [Abstract][Full Text] [Related]
4. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
[TBL] [Abstract][Full Text] [Related]
5. Current use of recombinant human erythropoietin (r-huEPO) in the management of symptomatic anaemia in patients with myelodysplastic syndromes (MDS).
Marques da Costa R
Sangre (Barc); 1994 Apr; 39(2):105-10. PubMed ID: 8059287
[TBL] [Abstract][Full Text] [Related]
6. Response to recombinant human erythropoietin in patients with myelodysplastic syndromes.
Stasi R; Brunetti M; Bussa S; Conforti M; Di Giulio C; Crescenzi A; Terzoli E; Vecchione A; Pagano A
Clin Cancer Res; 1997 May; 3(5):733-9. PubMed ID: 9815743
[TBL] [Abstract][Full Text] [Related]
7. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
[TBL] [Abstract][Full Text] [Related]
8. Preliminary results of amifostine administration in combination with recombinant human erythropoietin in patients with myelodysplastic syndromes.
Tsiara SN; Kapsali HD; Panteli K; Christou L; Bourantas KL
J Exp Clin Cancer Res; 2001 Mar; 20(1):35-8. PubMed ID: 11370827
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumours.
Nowrousian MR
Med Oncol; 1998 Aug; 15 Suppl 1():S19-28. PubMed ID: 9785333
[TBL] [Abstract][Full Text] [Related]
10. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
[TBL] [Abstract][Full Text] [Related]
11. Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response.
Viniou N; Terpos E; Galanopoulos A; Kritikou-Griva E; Akel S; Michalis E; Apostolidou E; Georgiadou D; Kouraklis A; Parharidou A; Kokkini G; Symeonidis A; Anagnostopoulos NI; Christakis JI; Tasiopoulou A; Loukopoulos D; Yataganas X
Ann Hematol; 2002 Apr; 81(4):182-6. PubMed ID: 11976818
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of refractory anemia by high-dose methylprednisolone associated with an increment in CD68-positive cells in bone marrow.
Motomura S; Motoji T; Okutomi K; Nishikawa T; Kasajima T; Mizoguchi H
Am J Hematol; 2001 Feb; 66(2):80-4. PubMed ID: 11421303
[TBL] [Abstract][Full Text] [Related]
13. Trilineage recovery by combination therapy with recombinant human granulocyte colony-stimulating factor and erythropoietin in patients with aplastic anemia and refractory anemia.
Bessho M; Jinnai I; Hirashima K; Saito M; Murohashi I; Ino H; Tsuji M; Fukuda M; Maruyama M; Kusumoto S
Stem Cells; 1994 Nov; 12(6):604-15. PubMed ID: 7533579
[TBL] [Abstract][Full Text] [Related]
14. High-dose (40,000 IU twice/week) alpha recombinant human erythropoietin as single agent in low/intermediate risk myelodysplastic syndromes: a retrospective investigation on 133 patients treated in a single institution.
Azzarà A; Carulli G; Galimberti S; Baratè C; Fazzi R; Cervetti G; Petrini M
Am J Hematol; 2011 Sep; 86(9):762-7. PubMed ID: 21850658
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human erythropoietin for the treatment of anaemia in patients with chronic idiopathic myelofibrosis.
Tsiara SN; Chaidos A; Bourantas LK; Kapsali HD; Bourantas KL
Acta Haematol; 2007; 117(3):156-61. PubMed ID: 17159338
[TBL] [Abstract][Full Text] [Related]
16. Improvement of anemia by recombinant erythropoietin in patients with myelodysplastic syndromes and aplastic anemia.
Bessho M; Jinnai I; Matsuda A; Saito M; Hirashima K
Int J Cell Cloning; 1990 Nov; 8(6):445-58. PubMed ID: 2273298
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.
Kasper C; Zahner J; Sayer HG
J Cancer Res Clin Oncol; 2002 Sep; 128(9):497-502. PubMed ID: 12242514
[TBL] [Abstract][Full Text] [Related]
18. [Recombinant human erythropoietin in the treatment of anemia associated with lymphoproliferative diseases--chronic lymphadenosis and multiple myeloma].
Haber J; Spicka I; Petruzelka L; Kolesková E; Straub J; Jonásová A; Pospísilová B
Vnitr Lek; 1996 Apr; 42(4):262-7. PubMed ID: 8693713
[TBL] [Abstract][Full Text] [Related]
19. Hypochromic red blood cells in low-risk myelodysplastic syndromes: effects of treatment with hemopoietic growth factors.
Ljung T; Bäck R; Hellström-Lindberg E
Haematologica; 2004 Dec; 89(12):1446-53. PubMed ID: 15590394
[TBL] [Abstract][Full Text] [Related]
20. Weekly administration of epoetin beta for chemotherapy-induced anemia in cancer patients: results of a multicenter, Phase III, randomized, double-blind, placebo-controlled study.
Tsuboi M; Ezaki K; Tobinai K; Ohashi Y; Saijo N
Jpn J Clin Oncol; 2009 Mar; 39(3):163-8. PubMed ID: 19164318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
